cjc 1295 ipamorelin muscle gain CJC-1295 + CJC-1295 + Ipamorelin - Beverly

USA, 97, 26802685

Together, they may address both the signaling and structural phases of tissue repair simultaneously

Tesamorelin is the most clinically validated option for visceral fat reduction, with FDA approval and robust trial data backing it

Tesamorelin Mechanism Type: GHRH analog Action: Mimics endogenous GHRH to directly stimulate the pituitary Primary Benefit: Increases GH to promote lipolysis and VAT reduction This direct pathway makes Tesamorelin highly targeted for fat loss and metabolic correction

L., Silva, C

AOD-9604 Regulatory Status As of June 2026, AOD-9604 is not FDA-approved for any therapeutic use